| (Values in U.S. Thousands) | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 |
| Sales | 9,390 | 7,410 | 0 | 0 | 0 |
| Sales Growth | +26.72% | unch | unch | unch | unch |
| Net Income | -21,660 | -16,240 | -3,450 | -1,970 | -1,930 |
| Net Income Growth | -33.37% | -370.72% | -75.13% | -2.07% | -14.20% |
Pelthos Therapeutics Inc (PTHS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Pelthos Therapeutics is a biopharmaceutical company. Its lead product includes ZELSUVMI(TM) topical gel. Pelthos Therapeutics, formerly known as Channel Therapeutics Corporation, is based in DURHAM, N.C.
Fiscal Year End Date: 12/31